China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Qinhuangdao Zizhu Pharmaceutical, received the Certificate of Suitability to Monograph of European Pharmacopoeia for the raw drug material, Dienogest.
Dienogest helps reduce the occurrence of acne and seborrhea and it is used to treat endometriosis, according to a Shanghai Stock Exchange disclosure on Thursday.
The certificate increased the domestic and foreign customers' recognition of the product, which could have a positive impact on its expansion in the international market, the Chinese pharmaceutical company said in the disclosure.